Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro- 2-indolinone derivatives

Arkivoc

Volumn 2006, Issue 1, 2006, Pages 109-118

  Terzioǧlu, Nalan ^a   Karali, Nilgün ^a   Gürsoy, Aysel ^a   Pannecouque, Christophe ^b   Leysen, Pieter ^b   Paeshuyse, Jan ^b   Neyts, Johan ^b   De Clercq, Erik ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1H 2 Indolinones; 4 thiazolidinones; Antiviral activity

Indexed keywords

EID: 27744585855     PISSN: 14246376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. (a) Teitz, Y.; Barko, N.; Abramoff, M.; Ronen, D.; Chemotherapy 1994, 40, 195.
2. (b) Teitz, Y.; Ronen, D.; Vansover, A.; Stematsky, T.; Riggs, J. L. Antiviral Res. 1994, 24, 305.
3. (c) Winter, J.; Hall, R.L.; Moyer, R.W. Virology 1995, 211, 462.
4. Sethi, M. L. Foye's Principles of Medicinal Chemistry, Lippincott Williams and Wilkins: Philadelphia, 2002, chapter 39.
5. (a) Zhang, H.; Vrang, L.; Bacbro, K.; Lind, P.; Sahlberg, C.; Unge, T.; Öberg, B. Antiviral Res. 1995, 28, 331.
6. (b) Mishra, V.; Pandeya, S. N.; DeClercq, E.; Pannecouque, C.; Witvrouw, M. Pharm. Acta Helv. 1998, 73, 215.
7. Sun, J.-H.; Lemm, J. A.; O'Boyle, D. R.; Colonno, R.; Gao, M. J. Virology 2003, 77, 6753.
8. (a) Rao, A.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Zappala, M. Il Farmaco 2003, 58, 115.
9. (b) Barreca, M. L.; Chimirri, A.; De Clercq, E.; De Luca, L.; Monforte, A. M.; Monforte, P.; Rao, A.; Zappalà, M. Il Farmaco 2003, 58, 259.
10. (c) Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Zappalà, M. Il Farmaco 2004, 59, 33.
11. (d) Rao, A.; Balzarini, J.; Carbone, A.; Chimirri, A.; De Clercq, E.; Monforte, A. M.; Monforte, P.; Pannecouque, C.; Zappalà, M. Antiviral Res. 2004, 63, 79.
12. (a) Petrov, I.; Grupce, O.; Stafilov, T. J. Mol. Struct. 1986, 142, 275.
13. (b) Naumov, P.; Anastasova, F. Spectr. Acta 2001, 57A, 469.
14. (c) Moustafa, M. A.; Bayomi, S. M.; El-Emam, A. A.; El-Kerdawy, M. M. Sci. Pharm. 1989, 57, 125.
15. Farghaly, A. M.; Habib, N. S.; Khalil, M. A.; El-Sayed, O. A.; Bistawroos, A. E. Arch. Pharm. (Weinheim) 1990, 323, 247.
16. (a) Omar, A.-M. M. E.; Eshba, N. H.; Salama, H. M. Arch Pharm. (Weinheim) 1984, 317, 701.
17. (b) Varma, R. S.; Singh, A. P.; Singh, S. P. Org. Mass Spectr. 1992, 27, 17.
18. Karali, N. Eur. J. Med. Chem. 2002, 37, 909.
19. Balzarini, J.; De Clercq, E.; Van Hemel, J.; Neyts, J.; Peys, E.; Ruttens, B.; Van der Eycken, J.; Vandenkerckhove, J. US Patent Appl. 20040209823, 514023000 (USPTO), A61K031/70 (Intl Class), 10/21/04; Davis, Brown, Koehn, Shors & Roberts, P.C. The Financial Center - Des Moines, IA, US.
20. (a) Leysen, P.; De Clercq, E.; Neyts, J.; Clin. Microbiol. Rev. 2000, 13, 67.
21. (b) De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P. C. Nature 1986, 323, 464.
22. (c) Balzarini, J.; Naesens, L.; Slachmuylders, J.; Niphuis, H.; Rosenberg, I.; Holy, A.; Schellekens, H.; De Clercq, E. AIDS 1991, 5, 21.
23. (d) Neyts, J.; Meerbach, A.; McKenna, P.; De Clercq, E. Antiviral Res. 1996, 30, 125.